Prescription opioids following herpes zoster: An observational study among insured adults, United States, 2007-2021
Journal of Opioid Management · 2024
DOI: 10.5055/jom.0845 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Opioid Management, 2024. Verfasst von Kathleen Dooling und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. …. Hauptthemen laut MEDLINE: Analgesics, Opioid, Herpes Zoster. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
The opioid overdose epidemic has resulted in hundreds of thousands of overdose deaths in the United States (US). One indication for opioids is herpes zoster (HZ)—a common painful condition with an estimated 1 million cases occurring annually in the US.
Objective
We aimed to characterize prescription opioid claims and trends among patients with HZ who were previously opioid naive.
Design
We used a cohort study involving three insurance claims databases in the US. We included all beneficiaries 18-64 years (commercial and Medicaid) and beneficiaries 65 years and older (Medicare) who were diagnosed with incident HZ during 2007-2021. We determined the proportion of opioid-naive patients with HZ who filled an opioid prescription within 30 days and 180 days following HZ diagnosis. We also examined trends over the study period, proportion receiving moderate, high dosages (50-89 morphine milligram equivalent [MME], and ≥90 MME per day), and long-term receipt.
Results
Among all three insurance databases, 2,595,837 patients had an incident episode of HZ and were opioid naive during the prior 6 months. Within 30 days following HZ, 623,515 (24 percent) filled a prescription for an opioid. The percentage with an opioid claim declined during 2007-2021 for all groups; 65 percent for commercially insured patients, 51 percent for Medicaid-insured patients, and 60 percent for Medicare-insured patients. Approximately 8-15 percent of all beneficiaries received moderate and 2-6 percent received high dosage opioids. Long-term prescription opioid use of at least 6 months was found in 7-12 percent of the patients.
Conclusions
Continuing trends in judicious opioid prescribing as well as use of recommended HZ vaccines may decrease opioid prescriptions for HZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. ORCID: https://orcid.org/0000-0002-7546-9327.
- Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. ORCID: https://orcid.org/0000-0002-5164-7555.
- Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. ORCID: https://orcid.org/0000-0002-7119-4645.
Zitieren
APA
Dooling, K., Leung, J., & Bohm, M. K. (2024). Prescription opioids following herpes zoster: An observational study among insured adults, United States, 2007-2021. Journal of Opioid Management. https://doi.org/10.5055/jom.0845
Vancouver
Dooling K, Leung J, Bohm MK. Prescription opioids following herpes zoster: An observational study among insured adults, United States, 2007-2021. Journal of Opioid Management. 2024. doi:10.5055/jom.0845
BibTeX
@article{Dooling2024,
author = {Dooling, Kathleen and Leung, Jessica and Bohm, Michele K},
title = {Prescription opioids following herpes zoster: An observational study among insured adults, United States, 2007-2021},
journal = {Journal of Opioid Management},
year = {2024},
doi = {10.5055/jom.0845}
}
EUVIMED